首頁 › 瀰漫性大B細胞淋巴瘤 › 德克薩斯州 › Dallas
Dallas, TX 的 瀰漫性大B細胞淋巴瘤 臨床試驗
13 項針對 瀰漫性大B細胞淋巴瘤 的研究正在 Dallas（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Texas Oncology - Dallas Fort Worth, Dallas
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- Texas Oncology - DFW ( Site 8000), Dallas
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- UT Southwestern Medical Center ( Site 0190), Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- University of Texas Southwestern, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
招募中觀察性研究
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- UT Southwestern Medical Center, Dallas
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
招募中2 期
- University of Texas Southwestern Medical Center, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
招募中1/2 期
- University of Texas Southwestern Medical Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- UT Southwestern Medical Center, Dallas
其他城市的 瀰漫性大B細胞淋巴瘤 試驗
- New York City, NY21 項研究
- Baldwin Park, CA19 項研究
- Chicago, IL18 項研究
- Houston, TX17 項研究
- Los Angeles, CA17 項研究
- Boston, MA16 項研究
- Milwaukee, WI16 項研究
- Nashville, TN15 項研究
- Portland, OR15 項研究
- Philadelphia, PA15 項研究
- Durham, NC14 項研究
- Seattle, WA12 項研究
Dallas 的其他研究
- 乳癌55 項研究
- 非小細胞肺癌52 項研究
- 轉移性癌症42 項研究
- 心臟衰竭42 項研究
- 癌症（所有類型）37 項研究
- 前列腺癌36 項研究
- 大腸直腸癌33 項研究
- 肥胖症30 項研究
- 卵巢癌28 項研究
- 膀胱癌27 項研究
- 肺癌27 項研究
- 子宮內膜癌24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。